Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-12-23

FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)

View source ↗

Summary

The FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) from H2-Pharma LLC. This action approves the supplemental request and upda…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZYPREXA RELPREVV (olanzapine pamoate)

Snippet

SUPPL AP for ZYPREXA RELPREVV (OLANZAPINE PAMOATE)